TeresaJanelleParliMD
Family Medicine • San Francisco, CAExecutive Director, Clinical Development 89bio, Inc.
Dr. Parli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Market St
San Francisco, CA 94105
Education & Training
Franciscan Health IndianapolisResidency, Family Medicine, 1995 - 1998
Indiana University School of MedicineClass of 1995
Certifications & Licensure
IN State Medical License 1996 - 2025
CA State Medical License 2004 - 2020
Clinical Trials
- Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia Start of enrollment: 2020 Sep 01
Publications & Presentations
PubMed
- 270 citationsEnzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg
European Urology. 2017-02-01 - 23 citationsThe FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.Deepak L Bhatt, Harold E Bays, Michael Miller, James E Cain 3rd, Katarzyna Wasilewska
Nature Medicine. 2023-07-01 - 82 citationsFive-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL TrialAndrew J. Armstrong, Ping Lin, Bertrand Tombal, Fred Saad, Celestia S. Higano
European Urology. 2020-09-01
Professional Memberships
- Member
Industry Relationships
- Executive Director, Clinical Development, 89bio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
